Carole Ho Denali Therapeutics Inc. (DNLI) insider trading activity

Carole Ho is Chief Medical Officer of Denali Therapeutics Inc.. Currently has a direct ownership of 175,673 shares of DNLI, which is worth approximately $2.6 Million. The most recent transaction as insider was on Jan 07, 2025, when has been sold 2,907 shares (Common Stock) at a price of $20.81 per share, resulting in proceeds of $60,494. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 176K

28.55% 3M change

22.33% 12M change

Total Value Held $2.6 Million

Carole Ho Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 07 2025	SELL Open market or private sale	$60,494 $20.81 p/Share	2,907 Reduced 1.63%	175,673 Common Stock
Jan 06 2025	SELL Open market or private sale	$247,796 $20.22 p/Share	12,255 Reduced 6.42%	178,580 Common Stock
Jan 03 2025	BUY Grant, award, or other acquisition	-	54,180 Added 22.11%	190,835 Common Stock
Nov 25 2024	BUY Exercise of conversion of derivative security	$12,134 $0.68 p/Share	17,845 Added 11.55%	136,655 Common Stock
Aug 21 2024	SELL Open market or private sale	$493,723 $24.68 p/Share	20,005 Reduced 14.41%	118,810 Common Stock
Aug 20 2024	SELL Open market or private sale	$58,356 $23.79 p/Share	2,453 Reduced 1.74%	138,815 Common Stock
Aug 13 2024	SELL Open market or private sale	$53,493 $22.89 p/Share	2,337 Reduced 1.63%	141,268 Common Stock
Feb 14 2024	SELL Open market or private sale	$24,994 $17.79 p/Share	1,405 Reduced 0.97%	143,605 Common Stock
Feb 13 2024	SELL Open market or private sale	$48,135 $17.29 p/Share	2,784 Reduced 1.88%	145,010 Common Stock
Jan 10 2024	SELL Open market or private sale	$88,785 $19.02 p/Share	4,668 Reduced 3.06%	147,794 Common Stock
Jan 03 2024	BUY Grant, award, or other acquisition	-	53,720 Added 24.85%	162,434 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	41,120 Added 22.83%	138,967 Common Stock
Aug 09 2022	BUY Grant, award, or other acquisition	-	22,500 Added 16.9%	110,597 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	31,000 Added 22.41%	107,316 Common Stock
Dec 06 2021	SELL Open market or private sale	$62,760 $42.52 p/Share	1,476 Reduced 1.9%	76,316 Common Stock

Also insider at

NGM

NGM BIOPHARMACEUTICALS INC Healthcare

BEAM

Beam Therapeutics Inc. Healthcare

Carole Ho

Chief Medical Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DNLI shares.

Notify only if

Value

Insider Trading

Get notified when an Denali Therapeutics Inc. insider buys or sells DNLI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Denali Therapeutics Inc.

Track Activities on DNLI

Account